YUNNAN BAIYAO(SZ:000538)2025-04-09 09:14Financial Performance - In 2024, the company achieved a revenue of CNY 40.033 billion, a year-on-year increase of 2.36% [2] - The net profit attributable to shareholders was CNY 4.749 billion, up 16.02% from CNY 4.094 billion in the previous year [2] - The net profit excluding non-recurring items reached CNY 4.523 billion, a 20.18% increase from CNY 3.764 billion [2] - Operating cash flow net amount was CNY 4.297 billion, growing by 22.68% [3] - The weighted average return on equity was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share were CNY 2.66, up 16.16% [2] Business Structure and Efficiency - The industrial revenue accounted for 36.14% of total revenue, with an industrial revenue growth rate of 5.30% [2] - The industrial gross margin was 65.93%, an increase of 1.69 percentage points [3] - Sales expenses decreased by 2.26% and management expenses decreased by 1.98% compared to the previous year [3] Pharmaceutical Division Performance - The pharmaceutical business group generated CNY 6.924 billion in revenue, a year-on-year increase of 11.8% [4] - The sales revenue of Yunnan Baiyao aerosol exceeded CNY 2.1 billion, growing over 26% [4] - Other traditional Chinese medicine products also saw significant growth, with Pudilan's sales nearing CNY 200 million, up over 22% [4] Consumer Goods and Channel Development - The company has a well-established national sales team for health products, maintaining a leading market share in Yunnan Baiyao toothpaste [5] - The company is optimizing its channel strategy, enhancing traditional offline channels while exploring new retail formats [5][6] Emerging Business Units - The medical device division achieved CNY 425 million in revenue, a 61% increase [7] - The health supplement division reported CNY 99.07 million in revenue, growing by 101% and achieving profitability for the first time [7] - The company is focusing on brand building and market expansion for its health supplement products [7]